Boston Trust Walden Corp Sells 3,373 Shares of Becton, Dickinson and Company $BDX

Posted by George Bondi on Jul 4th, 2026

Boston Trust Walden Corp cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 1.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 191,612 shares of the medical instruments supplier’s stock after selling 3,373 shares during the period. Boston Trust Walden Corp’s holdings in Becton, Dickinson and Company were worth $30,127,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BDX. Keybank National Association OH increased its position in Becton, Dickinson and Company by 9.5% in the 1st quarter. Keybank National Association OH now owns 13,410 shares of the medical instruments supplier’s stock valued at $2,108,000 after acquiring an additional 1,160 shares during the period. Smithbridge Asset Management Inc. DE bought a new stake in shares of Becton, Dickinson and Company in the first quarter worth $368,000. Stock Yards Bank & Trust Co. increased its holdings in Becton, Dickinson and Company by 18.3% in the first quarter. Stock Yards Bank & Trust Co. now owns 1,450 shares of the medical instruments supplier’s stock valued at $228,000 after purchasing an additional 224 shares during the period. Twin City Private Wealth LLC increased its holdings in Becton, Dickinson and Company by 8.0% in the first quarter. Twin City Private Wealth LLC now owns 16,492 shares of the medical instruments supplier’s stock valued at $2,593,000 after purchasing an additional 1,227 shares during the period. Finally, Stegent Equity Advisors Inc. raised its position in Becton, Dickinson and Company by 34.3% during the 1st quarter. Stegent Equity Advisors Inc. now owns 1,987 shares of the medical instruments supplier’s stock worth $312,000 after purchasing an additional 508 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BDX has been the subject of a number of recent analyst reports. Royal Bank Of Canada set a $175.00 target price on shares of Becton, Dickinson and Company in a research report on Tuesday, April 14th. Argus decreased their price objective on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a research report on Monday, March 23rd. Stifel Nicolaus dropped their target price on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Evercore upped their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 in a research report on Thursday, May 7th. Finally, Zacks Research upgraded Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Seven investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $181.00.

Read Our Latest Report on BDX

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $158.10 on Friday. The company has a market cap of $43.56 billion, a PE ratio of 40.02, a price-to-earnings-growth ratio of 11.19 and a beta of 0.21. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The business has a 50 day moving average price of $147.98 and a 200-day moving average price of $169.33. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.13. The company had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.Becton, Dickinson and Company’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities analysts anticipate that Becton, Dickinson and Company will post 12.62 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th were given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 106.33%.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 5,188 shares of company stock valued at $765,120. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.